Lexaria develops and out-licenses a delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. It has ten patents in the USA and Australia and has filed over 50 patent applications worldwide.
Lexaria’s annual revenue is still below $1 million/year.
Its technology offers a faster rate of intestinal absorption; higher amount delivered to the bloodstream; and taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria will hire a new corporate controller; head of legal division and other office staff. In the New Year, Lexaria expects to hire additional laboratory personnel as its R&D operations intensify.
As a result, Lexaria is issuing 240,000 stock options with an exercise price of US$1.06, that will vest 80,000 per year until April 15, 2021.
Lexaria has received US$110,000 from the exercise of warrants previously granted. (250,000 warrants with an exercise price of US$0.44). The warrant exercises are by third parties who are neither an officer nor a director of the Company.
Proceeds will be used for general corporate purposes.
Want to learn about other great cannabis investment opportunities? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has eight patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
Risk of Prosecution for Marijuana-Related Companies. If you are considering investing in a company that is connected to the marijuana industry, be aware that marijuana-related companies may be at risk of federal, and perhaps state, criminal prosecution. The Department of Treasury recently issued guidance noting: “[T]he Controlled Substances Act (“CSA”) makes it illegal under federal law to manufacture, distribute, or dispense marijuana. Many states impose and enforce similar prohibitions. Notwithstanding the federal ban, as of the date of this guidance, 20 states and the District of Columbia have legalized certain marijuana-related activity.”